



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Maytansinoid B

<b>Cat. No.:</b>	HY-148870		
<b>CAS No.:</b>	1628543-40-7		
<b>Molecular Formula:</b>	C <sub>36</sub> H <sub>51</sub> ClN <sub>4</sub> O <sub>10</sub>		
<b>Molecular Weight:</b>	735.26		
<b>Target:</b>	ADC Cytotoxin		
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (136.01 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		1.3601 mL	6.8003 mL	13.6006 mL
		5 mM		0.2720 mL	1.3601 mL	2.7201 mL
10 mM			0.1360 mL	0.6800 mL	1.3601 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (3.40 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (3.40 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	Maytansinoid B is a kind of ADC Cytotoxin. Maytansinoid B can be used to conjugates with antibodies to form antibody-drug conjugates (ADCs). Maytansinoids are known as antimetabolic agents, binding to tubulin and inhibiting microtubule assembly. Maytansinoids induces G2/M arrest in the cell cycle to induce apoptosis <sup>[1][2]</sup> .
<b>In Vitro</b>	Maytansinoids exhibits cytotoxic activity with 10-90 pM range across several tumor cell lines, including lymphoma lines <sup>[1]</sup> . Maytansinoid conjugates with anti-CD9, to form SAR3419 against B-cell malignancies <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

- [1]. Blanc V, et al. SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res. 2011 Oct 15;17(20):6448-58.
- [2]. Andreev Julian, et al. Bispecific antigen binding molecules that bind HER2, and methods of use thereof: World Intellectual Property Organization, WO2021174113. 2021-09-02.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA